U.S. Stocks Move: SELLAS Life Sciences plunges on October 28—REGAL endpoint triggered, efficacy pending, and high-level correction

SELLAS Life Sciences October 28 Significant Drop Interpretation

Keywords: REGAL endpoint trigger, efficacy pending, pullback from high level

1. On October 28, SELLAS announced that the REGAL Phase III trial had reached the preset 80th death event, initiating database lock, unblinding, and final statistical analysis; the company has not yet released the primary endpoint results, with preliminary topline data expected to be published this quarter. The efficacy of the trial remains to be verified, and there is ongoing uncertainty regarding clinical outcomes.

2. According to the data provided, SLS has accumulated a 168.70% increase year-to-date, but has fallen 16.56% in the past five days; before the clinical results are announced, the earlier significant gains and recent short-term pullback may intensify stock price volatility.

(Disclaimer: This content is generated by AI technology based on publicly available information, for reference only and does not constitute investment advice.)